Sanmai is a technology company.
Sanmai is transforming brain health care by harnessing trusted non-invasive technology into a new medical device while setting uncompromising standards of safety, efficacy and accessibility to all.
Sanmai has raised $12.0M across 1 funding round.
Sanmai has raised $12.0M in total across 1 funding round.
Sanmai Technologies is a clinical-stage medtech company developing non-invasive ultrasound neurotherapeutics for mental health and neurological disorders.[1][2] It combines low-intensity transcranial ultrasound stimulation with AI-driven software to deliver targeted brain treatments, addressing unmet needs in neuromodulation by offering safe, effective, and accessible alternatives to invasive therapies.[1][2] The company's first clinical ultrasound device is currently in trials and expected to be available soon, serving patients, clinicians, and research institutions seeking non-pharmaceutical options for brain health.[2] Backed by $12 million in funding from investors like One Mind Accelerator, Future Ventures, and PsyMed Ventures, Sanmai operates as a public benefit corporation focused on empowering well-being and autonomy.[1][3]
Sanmai Technologies was founded in 2020 in Sunnyvale (with headquarters now in Los Altos), California, by world-leading experts in neuromodulation, ultrasound, clinical science, and engineering.[1][2][3] Created as a public benefit corporation, the company emerged from the need for innovative, non-invasive brain therapeutics amid rising mental health challenges.[2] Early momentum came through an Incubator/Accelerator stage with key investors, including One Mind Accelerator, and the filing of 8 patents—primarily in neuroscience, neurophysiology, and medical imaging, such as imaging-based targeting for transcranial focused ultrasound systems (filed September 2023).[1] Pivotal progress includes advancing its first device into clinical trials, positioning Sanmai for near-term market entry.[2]
Sanmai stands out in the neuromodulation space through these key strengths:
Sanmai rides the wave of neuromodulation innovation, fueled by surging demand for non-drug mental health treatments amid global neurological disorder prevalence (e.g., depression, anxiety).[1][2] Timing aligns with advances in AI, medical imaging, and ultrasound tech, amplified by post-pandemic mental health crises and regulatory tailwinds for non-invasive devices.[1] Market forces like aging populations and precision medicine favor Sanmai, as transcranial ultrasound offers outpatient scalability over costly implants or lifelong meds.[2] By pioneering this category, Sanmai influences the ecosystem, partnering with research clinics and accelerators to accelerate adoption and spur competitors in brain health tech.[1][2]
Sanmai is poised for breakthrough with its lead device nearing availability, potentially capturing early-mover advantage in ultrasound neurotherapeutics amid a $20B+ neuromodulation market.[1][2][3] Trends like AI personalization and wearable medtech will propel growth, with clinical trial data and partnerships driving FDA pathways and scaling. Influence may evolve from innovator to ecosystem leader, licensing tech or expanding indications—ultimately redefining accessible brain health as this Los Altos trailblazer delivers on its mission for fuller lives.[2]
Sanmai has raised $12.0M in total across 1 funding round.
Sanmai's investors include CRV, Greylock, Innovation Endeavors, Sequoia Capital.
Sanmai has raised $12.0M across 1 funding round. Most recently, it raised $12.0M Series A in June 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2025 | $12.0M Series A | CRV, Greylock, Innovation Endeavors, Sequoia Capital |